705280-65-5

Usage

Uses

Used in Pharmaceutical and Medicinal Chemistry:
1H-Imidazole-4,5-dicarboxylic acid, 2-bromo-, 4,5-dimethyl ester is used as a building block and intermediate in the synthesis of various pharmaceuticals and bioactive molecules. The imidazole core structure is commonly found in many drugs, making 1H-Imidazole-4,5-dicarboxylic acid, 2-bromo-, 4,5-dimethyl ester a valuable asset in medicinal chemistry.
Used in Organic Synthesis:
1H-Imidazole-4,5-dicarboxylic acid, 2-bromo-, 4,5-dimethyl ester serves as a versatile building block in organic synthesis, allowing for the creation of new chemical compounds with potential applications in various fields. The bromo and methyl ester groups present in the molecule can be further modified or used as starting points for the synthesis of more complex molecules.
Used in Chemical Reactivity Studies:
The specific chemical reactivity and properties imparted by the bromo and methyl groups in 1H-Imidazole-4,5-dicarboxylic acid, 2-bromo-, 4,5-dimethyl ester make it a useful compound for studying chemical reactions and mechanisms. Researchers can utilize 1H-Imidazole-4,5-dicarboxylic acid, 2-bromo-, 4,5-dimethyl ester to explore the effects of different functional groups on reaction pathways and outcomes.

InChI:InChI=1/C7H7BrN2O4/c1-13-5(11)3-4(6(12)14-2)10-7(8)9-3/h1-2H3,(H,9,10)

Upstream product

• 3304-70-9 dimethyl imidazole-4,5-dicarboxylate 
• 945229-35-6 2-bromo-1-(2-deoxy-3,5-di-O-p-toluoyl-β-D-erythropentofuranosyl)imidazole-4,5-dicarboxylic acid dimethyl ester 

Downstream Products

• 872182-65-5 methyl 1-(p-benzyloxymethyl)-2-bromo-1H-imidazole-4,5-dicarboxylate 
• 867045-24-7 1-(2,3,5-tri-O-benzoyl-β-D-ribofuranosyl)-2-bromoimidazole-4,5-dicarboxylic acid dimethyl ester 
• 945229-35-6 2-bromo-1-(2-deoxy-3,5-di-O-p-toluoyl-β-D-erythropentofuranosyl)imidazole-4,5-dicarboxylic acid dimethyl ester 
• 808736-62-1 dimethyl 2-bromo-1-(2-chlorobenzyl)-1H-imidazole-4,5-dicarboxylate 

Relevant academic research and scientific papers

PYRIDINE DERIVATIVE

Provided is a pyridine derivative represented by formula (I), a prodrug thereof, a pharmaceutically acceptable salt of the pyridine derivative or the prodrug, or a solvate of the pyridine derivative, the prodrug or the pharmaceutically acceptable salt, wh

IMIDAZOPYRROLIDINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE

The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

Synthesis of 2-bromo-7-methyl-3,5-dihydro-imidazo[4,5-d]pyridazin-4-one and 3-alkyl-2-bromo-3,5-dihydro-imidazo[4,5-d]pyridazin-4-one and their selective elaboration

Two synthetic routes to the versatile 3,5-dihydro-imidazo[4,5-d]pyridazin-4-ones 2 and 5 have been developed that allow the production of multigram quantities without the need of any chromatographic purification. Broad and selective elaboration of the heteroaromatic scaffolds has also been accomplished.

Chemical and biological effects of substitution of the 2-position of ring-expanded ('fat') nucleosides containing the imidazo[4,5-e][1,3]diazepine-4,8-dione ring system: The role of electronic and steric factors on glycosidic bond stability and anti-HCV a

The attempted removal of the aralkyl group of 2-bromo-1-p-methoxybenzyl-6-octylimidazo[4,5-e][1,3]diazepine (ZP-33) with trifluoroacetic acid resulted in replacement of the bromo group with a carbonyl at position-2 in addition to the desired deprotection

Imidazopyridazinediones, their preparation and their use as pharmaceutical compositions

The invention relates to substituted imidazopyridazinediones of general formula wherein R1 and R4 are defined as in claim 1, the tautomers, the enantiomers, the diastereomers, the mixtures thereof and the salts thereof, which have va

IMIDAZOPYRIDAZINE DIONES, THE PRODUCTION THEREOF, AND THE USE OF THE SAME AS A MEDICAMENT

The invention relates to substituted imidazopyridazine diones of general formula (I) wherein R1 to R4 have the designation defined in patent claim 1. The invention also relates to the tautomers, enantiomers, diastereomers, mixtures and salts of said dione

Imidazole derivatives, their preparation and their use as intermediates for the preparation of pharmaceutical compositions and pesticides

The invention relates to new substituted imidazoles of general formula wherein R1 to R3 and X are defined as in the claims, the tautomers, the enantiomers, the diastereomers, the mixtures thereof and the salts thereof, and processes for preparing them and their use as intermediates for preparing pharmaceutical compositions or pesticides.

NOVEL IMIDAZOLE DERIVATIVES, THE PRODUCTION THEREOF, AND THE USE OF THE SAME AS INTERMEDIATE PRODUCTS FOR PRODUCING MEDICAMENTS AND PESTICIDES

The invention relates to novel substituted imidazoles of general formula (I) wherein R1 to R3 and X have the designations cited in the patent claims. The invention also relates to the tautomers, enantiomers, diastereromers, mixtures, and salts of said imidazoles, to methods for the production thereof, and to the use of the same as intermediate products for producing medicaments or pesticides.

New imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions

The present invention relates to substituted imidazo-pyridinones and imidazo-pyridazinones of general formula wherein Y and R1 to R4 are defined as in claim 1, the tautomers, enantiomers, diastereomers, the mixtures thereof and the salts thereof, which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).

Synthesis and in vitro anti-hepatitis B and C virus activities of ring-expanded ('fat') nucleobase analogues containing the imidazo[4,5-e][1,3] diazepine-4,8-dione ring system

As part of our structure-activity relationship studies, we report here the synthesis and in vitro anti-HBV and anti-HCV activities of a number of ring-expanded ('fat') nucleobases containing the imidazo[4,5-e][1,3]diazepine-4, 8-dione ring system. One of